Zota Health Care Ltd
Zota Health Care Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
2 of 3 strong
Not discussed on this call: fundraise, order book.
The short version
EBITDA margin for FY27 is expected to be higher than FY26 on a full-year basis. EBITDA margin for FY27 is expected to be higher than FY26 on a full-year basis.
From Zota Health Care Ltd's Q1 FY27 earnings-call transcript · updated 26 Aug 2026.
Revenue & Sales Performance
- EBITDA margin for FY27 is expected to be higher than FY26 on a full-year basis.
- Aggressive store expansion planned from Q3 and Q4 FY27, with around 650 store additions targeted for the full year.
- Mature stores (850+ stores) contribute significantly to profitability, offsetting new store expansion impact.
- Stores typically reach maturity within 12-18 months, with mature stores generating INR4.13 lakh+ GMV/month.
- Same-store sales growth (SSG) remains strong, with some cohorts showing 30%+ annualized growth.
- The company expects to become fully cash positive by end of Q4 FY27 or Q1 FY28.
- Marketing initiatives and brand-building expected to drive demand and penetration, supporting revenue growth.
- Significant headroom in market penetration as India has ~18-19 lakh pharmacies, while Davaindia has ~2,800 stores currently.
- Expect meaningful improvement in overall profitability and higher EBITDA margins than FY26 levels going forward.
Profitability & Margins
See what Zota Health Care Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Zota Health Care Limited made strategic investments in SKIA and UGO Generics, investing INR 2 crores each; both are in early stages with pilot rollouts beginning and expected progress from next quarter onward.
- The company acquired Globotask IT Consultancy to strengthen internal IT capabilities, enhance data security, reduce reliance on external IT vendors, and achieve cost benefits long-term.
- No explicit mention of immediate large-scale capital expenditure or capex plans; however, store expansion continues with planned addition of 600-650 stores in the current financial year, indicating ongoing investment in retail footprint and operations.
- Emphasis on brand building and marketing investments, including brand ambassadors, suggests continued strategic capital allocation toward marketing rather than heavy physical asset investments.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Zota Health Care Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Zota Health Care Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹163 Cr, net loss ₹14 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Zota Health Care Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Novartis India Ltd (Q1 FY27)
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
- IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Frequently Asked Questions
What were Zota Health Care Ltd Q1 FY27 results?
EBITDA margin for FY27 is expected to be higher than FY26 on a full-year basis. EBITDA margin for FY27 is expected to be higher than FY26 on a full-year basis.
What is Zota Health Care Ltd share price analysis?
Zota Health Care Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of N/A with a market cap of ₹3,766 Cr. Investors should review the full earnings analysis for detailed insights.
Is Zota Health Care Ltd planning capital expenditure?
Zota Health Care Limited made strategic investments in SKIA and UGO Generics, investing INR 2 crores each; both are in early stages with pilot rollouts beginning and expected progress from next quarter onward.
Keep Zota Health Care Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.